Remote Ischemic Conditioning in Cardiovascular Surgery.

abstract：BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a speci...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Zhou M,Ma C,Liu W,Liu H,Wang N,Kang Q,Li P

更新日期：2015-09-01 00:00:00

abstract：:BACKGROUND: The effects of sotalol on the 24-hour profile of the QT interval relative to that of the heart rate (HR) may be helpful in determining the time course of the drug's action in controlling cardiac arhythmias. This has not been previously determined. Thus, the objective of the current study was to evaluate th...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sharma PP,Sarma JS,Singh BN

更新日期：1999-01-01 00:00:00

abstract：:Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomit...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ilebekk A,Eriksen M,Sevre K,Aspelin T,Björkman JA,Lyberg T,Nordlander M

更新日期：2006-09-01 00:00:00

abstract：BACKGROUND:Brief periods of reocclusion (postconditioning) during early reperfusion reduce myocardial infarct size. Whether postconditioning has an effect on lethal ventricular arrhythmias independent of infarction in an in-vivo regional ischemia model is unknown. The purpose of this study was to determine if postcondi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kloner RA,Dow J,Bhandari A

更新日期：2006-03-01 00:00:00

abstract：:A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh N

更新日期：2002-04-01 00:00:00

abstract：:Effects of therapy with the potassium-channel opener and vasodilator nicorandil were studied in reperfused infarction of hypertrophied hearts by using magnetic resonance imaging (MRI), hemodynamic measurements, and histochemical staining. Aortic banding was performed on 22 Sprague-Dawley rats to induce left ventricula...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Schalla S,Higgins CB,Chujo M,Saeed M

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:Hypertension is a major cause of death and morbidity worldwide and is increasing in prevalence. The Renin-angiotensin system (RAS) is the most common mechanism involved in the pathophysiology of hypertension. Understanding the mechanism of the pathophysiologic processes will help direct potential therapeutic...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Zhao Y,Ma R,Yu X,Li N,Zhao X,Yu J

更新日期：2019-09-01 00:00:00

abstract：:Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist remains a mainstay in the prevention of ischemic events following coronary stent placement. Significant controversy exists regarding the optimal management of high platelet reactivity despite antiplatelet therapy; however this finding has been cons...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Weeks PA,Sieg A,Paruthi C,Rajapreyar I

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:In recent decades, clinical trials have played an increasingly important role in determining how we practice. Trial results proving that a clinical finding poses risk have led to interventions that try to reduce risk. Clinical trials proving that a particular therapy provides better outcome than another ther...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Reiffel JA

更新日期：2000-01-01 00:00:00

abstract：BACKGROUND:Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor. Statins are reported to increase 25(OH)VitD concentration. Animal studies suggest that ezetimibe is a moderate inhibitor of intestinal 25(OH)VitD absorption, but its effect in humans i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Liberopoulos EN,Makariou SE,Moutzouri E,Kostapanos MS,Challa A,Elisaf M

更新日期：2013-05-01 00:00:00

abstract：:Platelets are key mediators in the pathophysiology of atherothrombotic disease. Inappropriate platelet activation can lead to thrombosis and ischemic events. Platelet function testing has been used to monitor patient response to antiplatelet therapy. Variability in response to antiplatelet therapy may be due in part t...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Collet JP,Montalescot G

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Overexpression of the L-type voltage-dependent calcium channel alpha(1C)-subunit (L-VDCC OE) in transgenic mice results in adaptive hypertrophy followed by a maladaptive phase associated with a decrease in sarcoplasmic reticulum adenosine triphosphatase (SERCA)2a expression at 8 to 10 months of age. Overexpr...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Rubio M,Bodi I,Fuller-Bicer GA,Hahn HS,Periasamy M,Schwartz A

更新日期：2005-12-01 00:00:00

abstract：:Prior studies have suggested that intravenous diltiazem reduces the probability of spontaneous conversion of atrial fibrillation (AF) to sinus rhythm in the electrophysiology laboratory and in patients with postoperative AF. Whether diltiazem exerts the same effect in patients presenting to the emergency department (E...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hassan S,Slim AM,Kamalakannan D,Khoury R,Kakish E,Maria V,Ahmed S,Pires LA,Kronick SL,Oral H,Morady F

更新日期：2007-09-01 00:00:00

abstract：:BACKGROUND: Clinical trials have shown that the use of lipid-lowering agents in postmyocardial infarction (MI) patients reduces rates of subsequent coronary events, reduces coronary artery bypass surgery rates, and improves survival. Physician decisions to prescribe lipid-lowering drugs is influenced by a number of pa...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Khan M,Mukkamala A,Taylor DK,Espinosa A,Duff J

更新日期：1998-07-01 00:00:00

abstract：BACKGROUND:Limited data are available on the clinical management of atrial fibrillation (AF) and its outcomes from an Australian perspective. OBJECTIVE:To describe the appropriateness of antithrombotic prescribing for patients who presented with a diagnosis of AF to the Hawkesbury St John of God Hospital, New South Wa...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wertheimer G,Bereznicki LR

更新日期：2019-01-01 00:00:00

abstract：:BACKGROUND: We determined if a single administration of heparin or nonanticoagulant N-acetylheparin could reduce myocardial injury resulting from a 90-minute occlusion of the left circumflex coronary artery (LCX) and 6 hours of reperfusion in the anesthetized canine. METHODS AND RESULTS: Heparin (2 mg/kg), N-acetylhep...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gralinski MR,Driscoll EM,Friedrichs GS,DeNardis MR,Lucchesi BR

更新日期：1996-07-01 00:00:00

abstract：:The National Heart, Lung, and Blood Institute convened a Workshop on September 20-21, 2010, "New Horizons in Cardioprotection," to identify future research directions for cardioprotection against ischemia and reperfusion injury. Since the early 1970s, there has been evidence that the size of a myocardial infarction co...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kloner RA,Schwartz Longacre L

更新日期：2011-09-01 00:00:00

abstract：:Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy target many of the mechanical and structural aspects of heart failure...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Thompson KA,Philip KJ,Barbagelata A,Schwarz ER

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Dystrophin-deficient cardiomyopathy is a growing clinical problem without targeted treatments. We investigated whether nicorandil promotes cardioprotection in human dystrophin-deficient induced pluripotent stem cell (iPSC)-derived cardiomyocytes and the muscular dystrophy mdx mouse heart. METHODS AND RESULT...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Afzal MZ,Reiter M,Gastonguay C,McGivern JV,Guan X,Ge ZD,Mack DL,Childers MK,Ebert AD,Strande JL

更新日期：2016-11-01 00:00:00

abstract：:Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gallego P,Roldán V,Lip GY

更新日期：2014-01-01 00:00:00

abstract：:In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LD...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gomes FLT,Maranhão RC,Tavares ER,Carvalho PO,Higuchi ML,Mattos FR,Pitta FG,Hatab SA,Kalil-Filho R,Serrano CV Jr

更新日期：2018-11-01 00:00:00

abstract：:Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these ag...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Schrör K,Mehta P,Mehta JL

更新日期：2005-06-01 00:00:00

abstract：:Qiliqiangxin (QL), a traditional Chinese medicine, has been shown to be beneficial for chronic heart failure. However, whether QL can also improve endothelial cell function in diabetic rats remains unknown. Here, we investigated the effect of QL treatment on endothelial dysfunction by comparing the effect of QL to tha...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Chen F,Wu JL,Fu GS,Mou Y,Hu SJ

更新日期：2015-03-01 00:00:00

abstract：:Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of beta 1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chron...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Vittorio TJ,Zolty R,Kasper ME,Khandwalla RM,Hirsh DS,Tseng CH,Jorde UP,Ahuja K

更新日期：2008-03-01 00:00:00

abstract：:BACKGROUND: The electrophysiologic mechanisms of the persistence of atrial fibrillation (AF) after its initiation are not well understood. Therefore, the electrophysiologic characteristics of the right atrium were evaluated in an acute, pacing-induced model of AF in the pig in order to identify parameters associated w...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Rahme MM,Cotter B,Leistad E,Subudhayangkul S,Wadhwa M,Ungab G,Feld GK

更新日期：1999-04-01 00:00:00

abstract：INTRODUCTION:Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased s...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hanson SFL,Terry MH,Moretta DT,Power GG,Wilson SM,Alam F,Ahsan F,Blood AB,Giri PC

更新日期：2018-09-01 00:00:00

abstract：:Myocardial ischemic injury and cardioprotection are characterized by a cascade of molecular changes, which includes gene expression, protein expression, protein localization, interactions, and posttranslational modifications (PTMs). A systems biology approach allows the study of these genes and proteins on a large sca...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lotz C,Liem D,Ping P

更新日期：2011-09-01 00:00:00

abstract：:Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wolbrette DL,Hussain S,Maraj I,Naccarelli GV

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Although a gradual increase in heart rate (HR) during dobutamine stress testing (DST) is desired, few data exists regarding whether this is similarly achieved in patients of widely varying body mass index (BMI). Whether difference in BMI contributes to variation in the hemodynamic and symptomatic response to...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kittipovanonth M,Bernheim AM,Scott CG,Barnes ME,Shub C,Pellikka PA

更新日期：2011-06-01 00:00:00